According to in vitro and in vivo experiments, FGL1 leads to TRM suppression in HCC, and blockade of the LAG3 and FGL1 pathways might restore the TRM-mediated anti-tumor response in liver cancer. The gene discussed is FGL1; the disease is hepatocellular carcinoma.